Literature DB >> 30798300

Correction: Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.

.   

Abstract

Entities:  

Year:  2019        PMID: 30798300      PMCID: PMC6231569          DOI: 10.1136/bmjopen-2018-023090corr1

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


× No keyword cloud information.
Pacurariu A, Plueschke K, McGettigan P, et al. Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. BMJ Open 2018;8:e023090. doi: 10.1136/bmjopen-2018-023090. The following modifications are made to the original article: Table 1: The database ‘Information System of Parc de Salut del Mar’ from Spain is a secondary care database and not a primary care one. Table 2: Due to the previous mentioned change, in the cross-tabulation, the percentage of primary care/electronic medical records database decreased from 10 (29.4%) to 9 (26.5%) while the percentage of secondary care/electronic medical records increased from 2 (5.9%) to 3(8.8%). Section 3.2: The percentage of databases which capture data on hospital in-patient administered drugs increased from 5.8% to 8.8% due to reclassification of one database (PHARMO). The percentage of databases containing referrals for laboratory investigations increased from 19 (55.9%) to 20 (59%) and those containing referrals for imaging or other diagnostic procedures increased from 16 (47.1%) to 17 databases (50%). Section 3.4: One more database declared that they are in process of being converted to CDM (Information System of Parc de Salut del Mar), now five in total, compared to the four previously reported. Supplementary material contains minor changes for the databases IMASIS, and PHARMO: IMASIS was reclassified as a secondary care database and it was added that it is in process of being transformed via CDM. PHARMO was mentioned to contain hospital data, parent child linkage, screening results and test results (recoded from 0 to 1).
  1 in total

1.  Measuring the impact of risk communications: Robust analytical approaches are key.

Authors:  Peter Arlett
Journal:  Br J Clin Pharmacol       Date:  2020-02-16       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.